Skip to main
ADPT

Adaptive Biotechnologies (ADPT) Stock Forecast & Price Target

Adaptive Biotechnologies (ADPT) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 33%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Adaptive Biotechnologies is well-positioned for long-term success and its constant focus on innovation and expansion in the immune-driven medicine sector makes it a promising investment.

Bears say

Adaptive Biotechnologies is a company that has been growing at a consistent and accelerating rate in its MRD business, generating significant revenue and reaching profitability, with a diverse platform operating in both the diagnostic and pharma data services fields. However, concerns such as the termination of a collaboration agreement with Genentech and potential competition in the future may contribute to potential risks for the company. With a strong cash position and plans to expand its MRD business, the company may still have potential for growth but investors should closely monitor potential risks and industry developments in the coming years.

Adaptive Biotechnologies (ADPT) has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 33% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Adaptive Biotechnologies and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Adaptive Biotechnologies (ADPT) Forecast

Analysts have given Adaptive Biotechnologies (ADPT) a Buy based on their latest research and market trends.

According to 6 analysts, Adaptive Biotechnologies (ADPT) has a Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $20.17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $20.17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Adaptive Biotechnologies (ADPT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.